Business Description
CG Oncology Inc
NAICS : 541714
SIC : 2833
ISIN : US1569441009
Total Employee Number:
142Description
CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing its product candidate, cretostimogene grenadenorepvec, for patients with bladder cancer. The company's candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 116.6 | |||||
Equity-to-Asset | 0.95 | |||||
Debt-to-Equity | 0.01 | |||||
Debt-to-EBITDA | -0.04 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | 74.03 | |||||
Beneish M-Score | 4.36 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 0.6 | |||||
3-Year EBITDA Growth Rate | 36.2 | |||||
3-Year EPS without NRI Growth Rate | 43.8 | |||||
3-Year FCF Growth Rate | 40.1 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 438.16 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 54.07 | |||||
9-Day RSI | 56.87 | |||||
14-Day RSI | 57.37 | |||||
3-1 Month Momentum % | 12.01 | |||||
6-1 Month Momentum % | 23.54 | |||||
12-1 Month Momentum % | 156.46 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 22.22 | |||||
Quick Ratio | 22.2 | |||||
Cash Ratio | 21.77 | |||||
Days Inventory | 44 | |||||
Days Sales Outstanding | 42.42 | |||||
Days Payable | 272.12 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -8.3 | |||||
Shareholder Yield % | -5.7 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | -85.2 | |||||
Operating Margin % | -4056.18 | |||||
Net Margin % | -3602.68 | |||||
EBITDA Margin % | -4008.72 | |||||
FCF Margin % | -2879.62 | |||||
OCF Margin % | -2865.56 | |||||
ROE % | -26.51 | |||||
ROA % | -25.25 | |||||
ROIC % | -627.9 | |||||
3-Year ROIIC % | -507.66 | |||||
ROC (Joel Greenblatt) % | -1572.19 | |||||
ROCE % | -29.58 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 8 |
GF Value Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 1018.44 | |||||
PB Ratio | 6.73 | |||||
Price-to-Tangible-Book | 6.8 | |||||
EV-to-EBIT | -23.48 | |||||
EV-to-Forward-EBIT | -17.47 | |||||
EV-to-EBITDA | -23.76 | |||||
EV-to-Revenue | 952.43 | |||||
EV-to-Forward-Revenue | 1400.16 | |||||
EV-to-FCF | -33.07 | |||||
Price-to-GF-Value | 0.63 | |||||
| Price-to-Net-Current-Asset-Value | 6.97 | |||||
| Price-to-Net-Cash | 7.13 | |||||
Earnings Yield (Greenblatt) % | -4.26 | |||||
FCF Yield % | -2.58 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:CGON
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
CG Oncology Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 6.228 | ||
| EPS (TTM) ($) | -2.69 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | 55.7 | ||
| 14-Day RSI | 57.37 | ||
| 14-Day ATR ($) | 3.094368 | ||
| 20-Day SMA ($) | 75.728 | ||
| 12-1 Month Momentum % | 156.46 | ||
| 52-Week Range ($) | 26.04 - 80.97 | ||
| Shares Outstanding (Mil) | 88.64 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
CG Oncology Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
CG Oncology Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Annual report for 2026 | 2027-02-26 | In 183 days | ||
| Fourth quarter earnings results for 2026 | 2027-02-26 | In 183 days | ||
| Third quarter earnings results for 2026 | 2026-11-13 | In 78 days | ||
| Second quarter earnings results for 2026 | 2026-08-06 | 72.42 (+1.33%) | ||
| Goldman Sachs 47th Annual Global Healthcare Conference | 2026-06-09 14:40 | 54.40 (+0.00%) | ||
| General meeting for 2026 | 2026-06-04 10:00 | 54.42 (-1.66%) | ||
| Jefferies Global Healthcare Conference | 2026-06-03 10:30 | 55.53 (-5.09%) | ||
| RBC Capital Markets Global Healthcare Conference | 2026-05-20 14:35 | 63.30 (+1.88%) | ||
| Guidance call for 2026 | 2026-05-12 10:40 | 69.32 (+1.46%) | ||
| First quarter earnings results for 2026 | 2026-05-08 | 69.18 (+1.50%) |
Show
Entries
CG Oncology Inc Frequently Asked Questions
What is CG Oncology Inc(CGON)'s stock price today?
The current price of CGON is $78.42. The 52 week high of CGON is $80.97 and 52 week low is $26.04.
When is next earnings date of CG Oncology Inc(CGON)?
The next earnings date of CG Oncology Inc(CGON) is 2026-11-13 Est..
Does CG Oncology Inc(CGON) pay dividends? If so, how much?
CG Oncology Inc(CGON) does not pay dividend.
Guru Commentaries on NAS:CGON
Meridian Small Cap Growth Fund
Bullish
2026 Q1
What the manager wrote
CG Oncology, Inc. is a clinical-stage biotechnology company developing oncolytic immunotherapies for bladder cancer. The company targets non-muscle invasive bladder cancer, a large and underserved market where existing treatments carry significant side-effect profiles, positioning its lead candidate as a differentiated therapeutic alternative. Shares advanced sharply following the release of pivotal clinical data that exceeded expectations, reinforcing the competitive potential of the company’s lead program. The strong efficacy signals drove renewed investor interest and positioned the company favorably ahead of key regulatory milestones that could further unlock value.
Press Release
Articles on CG Oncology Inc
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers